Analysts Project Eli Lilly (LLY) to Deliver 21%+ Revenue Growth and 40%+ Adjusted Earnings Growth in 2026

1 month ago 13

Eli Lilly and Company (NYSE:LLY) is 1 of the 13 Best Extremely Profitable Stocks to Invest successful Now.

Analysts Project Eli Lilly (LLY) to Deliver 21%+ Revenue Growth and 40%+ Adjusted Earnings Growth successful  2026

Analysts Project Eli Lilly (LLY) to Deliver 21%+ Revenue Growth and 40%+ Adjusted Earnings Growth successful 2026

Pixabay/Public Domain

On February 2, 2026, Reuters reported that long-standing expectations that the planetary obesity cause marketplace would scope $150 cardinal implicit the adjacent decennary are being reconsidered amid declining U.S. prices for GLP-1 therapies and intensifying competition. The caller projections bespeak that the marketplace volition scope person to $100 cardinal by 2030, which is astir 30% little than erstwhile estimates. Furthermore, the $150 cardinal people is not expected to beryllium reached until 2035.

Citing unit from cash-pay contention and faster-than-expected generic entry, Jefferies reduced its highest marketplace estimation by 20% successful January. The firm’s expected marketplace size arsenic of 2035 stands astatine $80 billion.

Even with these revised assumptions, LSEG’s statement estimates inactive expect Eli Lilly and Company (NYSE:LLY) to present much than 21% gross maturation and much than 40% adjusted net maturation successful 2026 compared to 2025.

Against this backdrop of demand, Lilly outlined its strategical inaugural 2 days earlier.

On January 30, 2026, Eli Lilly and Company (NYSE:LLY) announced that it would conception a $3.5 cardinal pharmaceutical manufacturing installation successful Pennsylvania, which volition beryllium its 4th caller determination successful the United States. As GLP-1 contention accelerates, the works volition enactment connected injectable weight-loss cause accumulation similar retatrutide, with operation expected to statesman this twelvemonth and operations starting successful 2031.

Eli Lilly and Company (NYSE: LLY) develops and commercializes innovative medicines crossed diabetes, obesity, oncology, immunology, and neuroscience.

While we admit the imaginable of LLY arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the champion short-term AI stock.

READ NEXT: What Are the Best Stocks to Buy Right Now? and 10 Stocks Under $1 That Will Explode.

Disclosure: None.

Read Entire Article